DOW JONES28,992.41-227.57 -0.78%
S&P 5003,337.75-35.48 -1.05%
NASDAQ9,576.59-174.38 -1.79%

Canaccord Genuity Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces $198 Price Target

Canaccord Genuity analyst Edward Nash initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy rating and a $198 price target.

Benzinga · 01/30/2020 12:16

Canaccord Genuity analyst Edward Nash initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy rating and a $198 price target.